BIOWKS Bio-Works Technologies AB (publ)
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chromatography (IMAC) resin, size exclusion chromatography (SEC) resins, HTPD formats, screening kits, and desalting columns; and WorkBeads chromatography resins. Its products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications. Bio-Works Technologies AB (publ) founded in 2006 and is headquartered in Uppsala, Sweden.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Bio-Works Technologies (STO: BIOWKS)
›
Bio-Works Technologies (STO: BIOWKS) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 32 employees.
The shares were at 3.040 SEK on 18 November 2026, up 10.5% over 52 weeks. Its 52-week range is 2.130 SEK to 4.980 SEK: the price is 39.0% below the high and 42.7% above the low.
Its market capitalisation is 307.27M SEK.
Bio-Works Technologies reports return on equity of -31.0%, an operating margin of -10.7% and revenue down 42.0% year over year.
It holds more cash than debt, a net cash position of 43.81M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.